
LAVA Therapeutics NV
NASDAQ:LVTX

LAVA Therapeutics NV
Revenue
LAVA Therapeutics NV
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
LAVA Therapeutics NV
NASDAQ:LVTX
|
Revenue
$6.8m
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Pharming Group NV
AEX:PHARM
|
Revenue
$297.2m
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
30%
|
|
![]() |
ProQR Therapeutics NV
NASDAQ:PRQR
|
Revenue
€19.5m
|
CAGR 3-Years
101%
|
CAGR 5-Years
59%
|
CAGR 10-Years
51%
|
|
![]() |
Uniqure NV
NASDAQ:QURE
|
Revenue
$27.1m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
30%
|
CAGR 10-Years
16%
|
|
![]() |
argenx SE
XBRU:ARGX
|
Revenue
$2.2B
|
CAGR 3-Years
64%
|
CAGR 5-Years
95%
|
CAGR 10-Years
89%
|
|
![]() |
Merus NV
NASDAQ:MRUS
|
Revenue
$36.1m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

See Also
What is LAVA Therapeutics NV's Revenue?
Revenue
6.8m
USD
Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Revenue amounts to 6.8m USD.
What is LAVA Therapeutics NV's Revenue growth rate?
Revenue CAGR 3Y
25%
Over the last year, the Revenue growth was -65%. The average annual Revenue growth rates for LAVA Therapeutics NV have been 25% over the past three years .